Welcome to our dedicated page for NERVGEN PHARMA news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on NERVGEN PHARMA stock.
NervGen Pharma Corp (symbol: NGENF) is a clinical-stage biotech company focused on developing cutting-edge solutions for treating nervous system damage. Their lead drug candidate, NVG-291, is currently in a Phase 1b/2a clinical trial, targeting spinal cord injury as the initial indication. The company recently reported its financial and operational results, highlighting progress in recruitment for their clinical study and receiving Fast Track designation from the FDA. With a strong focus on innovative treatments and dedicated research efforts, NervGen is committed to enabling the nervous system to repair itself in cases of injury or disease.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF) has established an at-the-market equity program (ATM Program) allowing the company to issue and sell common shares through Stifel Nicolaus Canada Inc. The program has a limit of up to C$30 million in common shares, with sales occurring at prevailing market prices on the TSX Venture Exchange or other recognized marketplaces in Canada.
The ATM Program will run until December 19, 2026, unless terminated earlier. The company plans to use the net proceeds for general corporate purposes, including ongoing operations, working capital, research and development, intellectual property development, preclinical and clinical expenses, and potential future acquisitions. The program provides NervGen with enhanced flexibility for future additional financing needs.
NervGen Pharma reported Q3 2024 financial results, highlighting the approaching completion of target enrollment in the chronic cohort of their Phase 1b/2a clinical trial for NVG-291 in spinal cord injury. The company initiated preclinical studies for NVG-300 in ischemic stroke, ALS, and SCI. Financial results show cash position of $21.0 million as of September 30, 2024, with Q3 R&D expenses of $4.4 million and G&A expenses of $2.8 million. Net loss for Q3 was $5.2 million ($0.07 per share).
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focusing on neurorestorative therapeutics, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Mike Kelly will lead a fireside chat on November 18, 2024, at 10:20 a.m. EST. The conference will be held at the Lotte New York Palace Hotel from November 18-19, 2024. Management will be available for one-on-one investor meetings during the event, and a webcast of the presentation will be available for replay.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) has announced that target enrollment for the chronic cohort in its Phase 1b/2a clinical trial of NVG-291 for spinal cord injury (SCI) is nearing completion. The study (NCT05965700) is a proof-of-concept, double-blind, randomized placebo-controlled trial. Mike Kelly, NervGen's President & CEO, expressed excitement about the progress but noted challenges in forecasting enrollment due to various factors and the study's novel design.
The company remains confident in advancing NVG-291 and will provide updates when enrollment is completed and when topline data is expected. NervGen plans to allow all subjects who have started the screening process when the 20-subject target is reached to enroll if they meet the criteria, potentially resulting in more than 20 subjects in the chronic cohort.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company, announced that its Chief Medical Officer, Daniel Mikol, MD, Ph.D., will present at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium on September 27-28, 2024, in Atlanta, Georgia.
Dr. Mikol's presentation, titled 'Clinical Trials in Spinal Cord Injury ... Lost in Translation?', will be delivered during Session 6 on Saturday, September 28, from 11:00 a.m. to 11:20 a.m. EDT at the Atlanta Marriott Marquis. He will discuss the challenges of translating results from animal models to human clinical trials for spinal cord injury (SCI).
The U2FP Symposium is a significant event that gathers research scientists, clinicians, investors, SCI survivors, and family members to promote knowledge, collaboration, and empowerment for stakeholders dedicated to finding a cure for SCI.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company, announced that its Chief Medical Officer, Dr. Daniel Mikol, will present at the 63rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting in Antwerp, Belgium, on September 23, 2024. Dr. Mikol will provide a clinical trial update on the Phase 1b/2a study of NVG-291 in individuals with subacute or chronic spinal cord injury (SCI).
The presentation will cover the trial design, rationale for evaluating clinical and electrophysiological measures, and baseline characteristics of randomized subjects. NVG-291 has shown promise in preclinical studies for promoting functional recovery through neural repair mechanisms. The company hopes that the trial results will demonstrate the potential of NVG-291 to enable neural repair in SCI patients and support further investigation.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on developing treatments for nervous system damage, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.
Mr. Mike Kelly, President & CEO of NervGen, will deliver a presentation on Tuesday, September 10, 2024, at 9:30 a.m. EDT. The company's management team will also be available for one-on-one meetings with investors throughout the conference, providing an opportunity for in-depth discussions about NervGen's innovative approaches to treating nervous system damage.
NervGen Pharma reported Q2 2024 financial results and operational updates for its Phase 1b/2a clinical trial of NVG-291 for spinal cord injury (SCI). Key highlights include:
1. Targeting completion of enrollment in the chronic cohort by Q3 2024
2. Protocol amendment submitted to enhance enrollment in the subacute cohort
3. Introduction of NVG-300 for preclinical studies in ischemic stroke, ALS, and SCI
4. Cash position of $26.6 million as of June 30, 2024
5. Q2 2024 net loss of $7.8 million ($0.11 per share)
The company is implementing strategies to increase trial awareness and participant support, while also expanding its pipeline with NVG-300, potentially providing future partnering opportunities.
NervGen Pharma Corp. (NGENF), a clinical-stage biotech firm focused on nervous system damage treatments, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event will take place from August 13-15, 2024, at the InterContinental Boston Hotel.
Key points:
- CEO Mike Kelly will present on August 13, 2024, at 10:00 a.m. EDT
- Management will be available for one-on-one investor meetings
- A webcast of the presentation will be accessible online and available for replay after the event
This conference provides NervGen an opportunity to showcase its innovative solutions and engage with potential investors, potentially impacting its stock performance.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical stage biotech company focused on treating nervous system damage, has granted stock options to employees and consultants. The company issued 30,000 options to employees, exercisable at $2.98 per share for 10 years, vesting equally every six months over two years. Additionally, 15,000 options were granted to existing consultants providing investor relations services, exercisable at the same price for five years, vesting equally every three months over one year. These options comply with TSX Venture Exchange policies and the company's stock option plan.
FAQ
What is the current stock price of NERVGEN PHARMA (NGENF)?
What is the market cap of NERVGEN PHARMA (NGENF)?
What is NervGen Pharma Corp focused on?
What is NVG-291, and what is its current status?
What recent achievements has NervGen reported?
What sets NervGen apart in the biotech industry?
